Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Han, Kunkun ^a   Xu, Xin ^a   Chen, Guodong ^a   Zeng, Yuanying ^a   Zhu, Jingyu ^a   Du, Xiaolin ^a   Zhang, Zubin ^a   Cao, Biyin ^a   Liu, Zhaopeng ^b   Mao, Xinliang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

BENC 511; Drug discovery; Multiple myeloma; Phosphatidylinositol 3 kinase (PI3K) AKT signaling pathway; S14161

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; CASPASE 3; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MICE; MICE, NUDE; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894266310     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-9     Document Type: Article

References (42)

1. PIP2 and PIP3: complex roles at the cell surface. Czech MP, Cell 2000 100 6 603 606 10.1016/S0092-8674(00)80696-0 10761925
2. Phosphoinositide 3-kinase signalling pathways. Cantrell DA, J Cell Sci 2001 114 Pt 8 1439 1445 11282020 (Pubitemid 32427831)
3. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H, J Hematol Oncol 2012 5 16 10.1186/1756-8722-5-16 22534171
4. PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases. Shenker BJ, Ali H, Boesze-Battaglia K, Curr Pharm Des 2011 17 34 3815 3822 10.2174/138161211798357926 22103853
5. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D, J Hematol Oncol 2013 6 1 88 10.1186/1756-8722-6-88 24261963
6. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 7 489 501 10.1038/nrc839 12094235 (Pubitemid 37328931)
7. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA, Proc Natl Acad Sci USA 2009 106 1 268 273 10.1073/pnas.0810956106 19116269
8. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Polak R, Buitenhuis M, Blood 2012 119 4 911 923 10.1182/blood-2011-07-366203 22065598
9. Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Fang X, Zhou X, Wang X, Biomark Res 2013 1 1 30 10.1186/2050-7771-1-30 24252186
10. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Li J, Zhu J, Cao B, Mao X, Curr Pharm Des 2014 20 1 125 35 10.2174/13816128113199990638 24001224
11. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, et al. Blood 2011 117 6 1986 1997 10.1182/blood-2010-05-284810 21135258
12. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Falasca M, Curr Pharm Des 2010 16 12 1410 1416 10.2174/138161210791033950 20166984
13. The PI3K pathway as drug target in human cancer. Courtney KD, Corcoran RB, Engelman JA, J Clin Oncol 2010 28 6 1075 1083 10.1200/JCO.2009.25.3641 20085938
14. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Wu P, Hu YZ, Curr Med Chem 2010 17 35 4326 4341 10.2174/ 092986710793361234 20939811
15. Exploiting the PI3K/AKT pathway for cancer drug discovery. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, Nat Rev Drug Discov 2005 4 12 988 1004 10.1038/nrd1902 16341064
16. Cell trafficking in multiple myeloma. Bianchi G, Kumar S, Ghobrial IM, Roccaro AM, Open J Hematol 2012 3 Suppl 1 1 17
17. Potent and selective inhibitors of PI3Kdelta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, et al. Bioorg Med Chem Lett 2012 22 13 4296 4302 10.1016/j.bmcl.2012.05.027 22672799
18. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W, Oncogene 2003 22 40 6289 6295 10.1038/sj.onc.1206718 13679867 (Pubitemid 37281658)
19. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S, PLoS One 2012 7 11 50005 10.1371/journal.pone.0050005 23185517
20. The AKT kinase is activated in multiple myeloma tumor cells. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A, Blood 2001 98 9 2853 2855 10.1182/blood.V98.9.2853 11675360
21. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ, Blood 2011 119 8 1897 1900 22210877
22. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, et al. Mol Cancer Ther 2012 11 8 1747 1757 10.1158/1535-7163.MCT-11-1021 22653967
23. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC, Expert Opin Drug Metab Toxicol 2012 8 5 623 633 10.1517/17425255.2012.681376 22512706
24. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H, J Surg Res 2010 160 1 90 101 10.1016/j.jss.2008.08.016 19560785
25. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D, Haematologica 2010 95 5 819 828 10.3324/haematol.2009.013797 19951971
26. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B, Blood 2010 115 22 4455 4463 10.1182/blood-2009-10-251082 20299510
27. Development of PI3K inhibitors: lessons learned from early clinical trials. Rodon J, Dienstmann R, Serra V, Tabernero J, Nat Rev Clin Oncol 2013 10 3 143 153 10.1038/nrclinonc.2013.10 23400000
28. [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression]. Guo YQ, Chen SL, Zhonghua Xue Ye Xue Za Zhi 2006 27 4 231 234 16875552
29. Immunomodulatory assays to study structure-activity relationships of thalidomide. Shannon EJ, Morales MJ, Sandoval F, Immunopharmacology 1997 35 3 203 212 10.1016/S0162-3109(96)00149-X 9043933 (Pubitemid 27063819)
30. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, et al. Blood 2000 96 9 2943 2950 11049970
31. Thalidomide as a nitric oxide synthase inhibitor and its structural development. Shimazawa R, Sano H, Tanatani A, Miyachi H, Hashimoto Y, Chem Pharm Bull (Tokyo) 2004 52 4 498 499 10.1248/cpb.52.498 15056977 (Pubitemid 41694747)
32. Structural development of biological response modifiers based on thalidomide. Hashimoto Y, Bioorg Med Chem 2002 10 3 461 479 10.1016/S0968- 0896(01)00308-X 11814832 (Pubitemid 34112438)
33. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. Richardson P, Anderson K, J Clin Oncol 2004 22 16 3212 3214 10.1200/JCO.2004.05.984 15249587 (Pubitemid 41103674)
34. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B, Proc Natl Acad Sci USA 2010 107 25 11381 11386 10.1073/pnas.0906461107 20534549
35. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Ghigo A, Damilano F, Braccini L, Hirsch E, Bioessays 2010 32 3 185 196 10.1002/bies.200900150 20162662
36. Phosphorylation of AKT: a mutational analysis. Hart JR, Vogt PK, Oncotarget 2011 2 6 467 476 21670491
37. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Markman B, Dienstmann R, Tabernero J, Oncotarget 2010 1 7 530 543 21317449
38. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Chung J, Kuo CJ, Crabtree GR, Blenis J, Cell 1992 69 7 1227 1236 10.1016/0092-8674(92)90643-Q 1377606
39. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N, Genes Dev 1998 12 4 502 513 10.1101/gad.12.4.502 9472019 (Pubitemid 28101013)
40. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N, Cancer Cell 2010 18 1 39 51 10.1016/j.ccr.2010.05.023 20609351
41. Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro. Yin SQ, Shi M, Kong TT, Zhang CM, Han K, Cao B, Zhang Z, Du X, Tang LQ, Mao X, et al. Bioorg Med Chem Lett 2013 23 11 3314 3319 10.1016/j.bmcl.2013.03.097 23601711
42. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X, Int J Cancer 2012 131 10 2411 2419 10.1002/ijc.27504 22362357